Secondary nonresponsiveness to new bulk botulinum toxin A (BCB2024).
Identifieur interne : 000921 ( Ncbi/Merge ); précédent : 000920; suivant : 000922Secondary nonresponsiveness to new bulk botulinum toxin A (BCB2024).
Auteurs : Brad A. Racette [États-Unis] ; Mikula Stambuk ; Joel S. PerlmutterSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2002.
English descriptors
- KwdEn :
- MESH :
- chemical , pharmacology : Botulinum Toxins, Type A.
- drug effects : Blinking.
- drug therapy : Blepharospasm.
- chemical , therapeutic use : Botulinum Toxins, Type A.
- Female, Humans, Middle Aged, Treatment Outcome.
Abstract
We report on a patient with cranio-cervical dystonia injected with the new, lower protein formulation of botulinum toxin A who developed secondary resistance to this toxin. Subsequent injections with botulinum toxin B provided substantial reduction of blepharospasm. This is the first reported case of secondary resistance to the new preparation of botulinum toxin A.
DOI: 10.1002/mds.10209
PubMed: 12360571
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 003930
- to stream PubMed, to step Curation: 003930
- to stream PubMed, to step Checkpoint: 003942
Links to Exploration step
pubmed:12360571Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Secondary nonresponsiveness to new bulk botulinum toxin A (BCB2024).</title>
<author><name sortKey="Racette, Brad A" sort="Racette, Brad A" uniqKey="Racette B" first="Brad A" last="Racette">Brad A. Racette</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Neurology and Neurological Surgery (Neurology), Washington University School of Medicine, St. Louis, Missouri 63110, USA. racetteb@neuro.wustl.edu</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology and Neurological Surgery (Neurology), Washington University School of Medicine, St. Louis, Missouri 63110</wicri:regionArea>
<orgName type="university">École de médecine (Université Washington de Saint-Louis)</orgName>
<placeName><settlement type="city">Saint-Louis (Missouri)</settlement>
<region type="state">Missouri (État)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Stambuk, Mikula" sort="Stambuk, Mikula" uniqKey="Stambuk M" first="Mikula" last="Stambuk">Mikula Stambuk</name>
</author>
<author><name sortKey="Perlmutter, Joel S" sort="Perlmutter, Joel S" uniqKey="Perlmutter J" first="Joel S" last="Perlmutter">Joel S. Perlmutter</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2002">2002</date>
<idno type="RBID">pubmed:12360571</idno>
<idno type="pmid">12360571</idno>
<idno type="doi">10.1002/mds.10209</idno>
<idno type="wicri:Area/PubMed/Corpus">003930</idno>
<idno type="wicri:Area/PubMed/Curation">003930</idno>
<idno type="wicri:Area/PubMed/Checkpoint">003942</idno>
<idno type="wicri:Area/Ncbi/Merge">000921</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Secondary nonresponsiveness to new bulk botulinum toxin A (BCB2024).</title>
<author><name sortKey="Racette, Brad A" sort="Racette, Brad A" uniqKey="Racette B" first="Brad A" last="Racette">Brad A. Racette</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Neurology and Neurological Surgery (Neurology), Washington University School of Medicine, St. Louis, Missouri 63110, USA. racetteb@neuro.wustl.edu</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology and Neurological Surgery (Neurology), Washington University School of Medicine, St. Louis, Missouri 63110</wicri:regionArea>
<orgName type="university">École de médecine (Université Washington de Saint-Louis)</orgName>
<placeName><settlement type="city">Saint-Louis (Missouri)</settlement>
<region type="state">Missouri (État)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Stambuk, Mikula" sort="Stambuk, Mikula" uniqKey="Stambuk M" first="Mikula" last="Stambuk">Mikula Stambuk</name>
</author>
<author><name sortKey="Perlmutter, Joel S" sort="Perlmutter, Joel S" uniqKey="Perlmutter J" first="Joel S" last="Perlmutter">Joel S. Perlmutter</name>
</author>
</analytic>
<series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2002" type="published">2002</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Blepharospasm (drug therapy)</term>
<term>Blinking (drug effects)</term>
<term>Botulinum Toxins, Type A (pharmacology)</term>
<term>Botulinum Toxins, Type A (therapeutic use)</term>
<term>Female</term>
<term>Humans</term>
<term>Middle Aged</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Botulinum Toxins, Type A</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Blinking</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Blepharospasm</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Botulinum Toxins, Type A</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Female</term>
<term>Humans</term>
<term>Middle Aged</term>
<term>Treatment Outcome</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We report on a patient with cranio-cervical dystonia injected with the new, lower protein formulation of botulinum toxin A who developed secondary resistance to this toxin. Subsequent injections with botulinum toxin B provided substantial reduction of blepharospasm. This is the first reported case of secondary resistance to the new preparation of botulinum toxin A.</div>
</front>
</TEI>
<pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">12360571</PMID>
<DateCreated><Year>2002</Year>
<Month>10</Month>
<Day>02</Day>
</DateCreated>
<DateCompleted><Year>2003</Year>
<Month>01</Month>
<Day>08</Day>
</DateCompleted>
<DateRevised><Year>2010</Year>
<Month>11</Month>
<Day>18</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN>
<JournalIssue CitedMedium="Print"><Volume>17</Volume>
<Issue>5</Issue>
<PubDate><Year>2002</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Movement disorders : official journal of the Movement Disorder Society</Title>
<ISOAbbreviation>Mov. Disord.</ISOAbbreviation>
</Journal>
<ArticleTitle>Secondary nonresponsiveness to new bulk botulinum toxin A (BCB2024).</ArticleTitle>
<Pagination><MedlinePgn>1098-100</MedlinePgn>
</Pagination>
<Abstract><AbstractText>We report on a patient with cranio-cervical dystonia injected with the new, lower protein formulation of botulinum toxin A who developed secondary resistance to this toxin. Subsequent injections with botulinum toxin B provided substantial reduction of blepharospasm. This is the first reported case of secondary resistance to the new preparation of botulinum toxin A.</AbstractText>
<CopyrightInformation>Copyright 2002 Movement Disorder Society</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Racette</LastName>
<ForeName>Brad A</ForeName>
<Initials>BA</Initials>
<AffiliationInfo><Affiliation>Department of Neurology and Neurological Surgery (Neurology), Washington University School of Medicine, St. Louis, Missouri 63110, USA. racetteb@neuro.wustl.edu</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Stambuk</LastName>
<ForeName>Mikula</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y"><LastName>Perlmutter</LastName>
<ForeName>Joel S</ForeName>
<Initials>JS</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>NS31001</GrantID>
<Acronym>NS</Acronym>
<Agency>NINDS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Mov Disord</MedlineTA>
<NlmUniqueID>8610688</NlmUniqueID>
<ISSNLinking>0885-3185</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>EC 3.4.24.69</RegistryNumber>
<NameOfSubstance UI="D019274">Botulinum Toxins, Type A</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001764">Blepharospasm</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D001767">Blinking</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D019274">Botulinum Toxins, Type A</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year>
<Month>10</Month>
<Day>3</Day>
<Hour>4</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2003</Year>
<Month>1</Month>
<Day>9</Day>
<Hour>4</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2002</Year>
<Month>10</Month>
<Day>3</Day>
<Hour>4</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">12360571</ArticleId>
<ArticleId IdType="doi">10.1002/mds.10209</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Missouri (État)</li>
</region>
<settlement><li>Saint-Louis (Missouri)</li>
</settlement>
<orgName><li>École de médecine (Université Washington de Saint-Louis)</li>
</orgName>
</list>
<tree><noCountry><name sortKey="Perlmutter, Joel S" sort="Perlmutter, Joel S" uniqKey="Perlmutter J" first="Joel S" last="Perlmutter">Joel S. Perlmutter</name>
<name sortKey="Stambuk, Mikula" sort="Stambuk, Mikula" uniqKey="Stambuk M" first="Mikula" last="Stambuk">Mikula Stambuk</name>
</noCountry>
<country name="États-Unis"><region name="Missouri (État)"><name sortKey="Racette, Brad A" sort="Racette, Brad A" uniqKey="Racette B" first="Brad A" last="Racette">Brad A. Racette</name>
</region>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000921 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 000921 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Ncbi |étape= Merge |type= RBID |clé= pubmed:12360571 |texte= Secondary nonresponsiveness to new bulk botulinum toxin A (BCB2024). }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:12360571" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \ | NlmPubMed2Wicri -a MovDisordV3
![]() | This area was generated with Dilib version V0.6.23. | ![]() |